The Center
Multiple Sclerosis Center Dresden
Patient Information
Contact MSC
Physicians & Nurses
Study Team
Neuropsychology
Mobility Center
The Mobility Center
Walking Assessment
Jump Assessment
DIERS
EMIQ
Projects
Neuroimmunological Laboratory
The NIL
Neurofilament light chain
Autonomic & Neuroendocrinological Functional Laboratory
The ANF
ANF Assessment
MS Living Lab
Management & Science
Team Management & Science
Projects
eHealth & Analytics
MSDS 3D
MSDS Clinic & Practice
MS-HRS
MTRS
Multiple Sclerosis Management
Aktuelles
Neuigkeiten
Publikationen
Veranstaltungen
Adventssymposium
Multiple Sklerose 360°
Welt-MS-Tag 2021
Doktorarbeiten
Jobs
Kontakt
Podcasts & Newsletter
Newsletter
Patienten-Podcast
Ärzte-Podcast
Neurovision
Immune cell calender 25
Sherlock-MS-Blog
Studien
Interventionelle Studien
B-SHUTTLE
Nicht-interventionelle Studien
MS PATHS
Konectom
Sprachanalyse
English (UK)
Deutsch
English (UK)
Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety
MS Treatments
Jahr
Publikationsjahr
2022
Autoren
Autorenliste der Publikation
Moser T, Ziemssen T, Sellner J.
Verlag
Publisher-Information
Wien Med Wochenschr 2022;172(15-16):365-372.
Link
Zur Publikation (externer Server)
https://doi.org/10.1007/s10354-022-00931-4
Tags
Forschungsthemen
Multiple Sklerose
MS Behandlung
Treatments
2022
Extensive T-Cell Profiling Following SARS-CoV-2 mRNA Vaccination in Multiple Sclerosis Patients Treated with DMTs
NIL
Jahr
2025
Long-term efficacy and safety of alemtuzumab in participants with highly active MS: TOPAZ clinical trial and interim analysis of TREAT-MS real-world study
MS Treatments
Jahr
2025
Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS
MS Treatments
Jahr
2025
A plain language summary of a study exploring the experiences of people with relapsing–remitting multiple sclerosis: what symptoms and impacts of the disease matter most and how can they be evaluated better?
MS Treatments
Jahr
2025
Cost–consequence analysis of early vs. delayed natalizumab use in highly active relapsing–remitting multiple sclerosis: a simulation study
MASC
Jahr
2025
